NORWAY - Ferd lists Pronova BioPharma with market-cap of NOK 6.9bn

Ferd Private Equity (FPE I) has listed Pronova BioPharma (previously Pronova Biocare), a Norwegian manufacturer of Omega-3 pharmaceutical products, on the Oslo Stock Exchange for an offer price of NOK 23 per share. The total offer size is NOK 2.7bn (including an over-allotment option), and based on the set offer price, the company will have a market capitalisation of NOK 6.9bn (EUR 900m). Prior to the listing, Ferd held 93% of the shares, but at the completion of the offer, the investor will hold approximately 58.3% of the shareholding. Carnegie and UBS acted as joint global coordinator and joint bookrunners for the offering.